| Magnetic resonance in the era of molecular imaging of cancer. | |
| | |
MedLine Citation:
|
PMID: 21524870 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Magnetic resonance imaging (MRI) has played an important role in the diagnosis and management of cancer since it was first developed, but other modalities also continue to advance and provide complementary information on the status of tumors. In the future, there will be a major continuing role for noninvasive imaging in order to obtain information on the location and extent of cancer, as well as assessments of tissue characteristics that can monitor and predict treatment response and guide patient management. Developments are currently being undertaken that aim to provide improved imaging methods for the detection and evaluation of tumors, for identifying important characteristics of tumors such as the expression levels of cell surface receptors that may dictate what types of therapy will be effective and for evaluating their response to treatments. Molecular imaging techniques based mainly on radionuclide imaging can depict numerous, specific, cellular and molecular markers of disease and have unique potential to address important clinical and research challenges. In this review, we consider what continuing and evolving roles will be played by MRI in this era of molecular imaging. We discuss some of the challenges for MRI of detecting imaging agents that report on molecular events, but highlight also the ability of MRI to assess other features such as cell density, blood flow and metabolism which are not specific hallmarks of cancer but which reflect molecular changes. We discuss the future role of MRI in cancer and describe the use of selected quantitative imaging techniques for characterizing tumors that can be translated to clinical applications, particularly in the context of evaluating novel treatments. |
| | |
Authors:
|
John C Gore; H Charles Manning; C Chad Quarles; Kevin W Waddell; Thomas E Yankeelov |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review Date: 2011-04-27 |
Journal Detail:
|
Title: Magnetic resonance imaging Volume: 29 ISSN: 1873-5894 ISO Abbreviation: Magn Reson Imaging Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-23 Completed Date: 2011-09-15 Revised Date: 2012-02-23 |
Medline Journal Info:
|
Nlm Unique ID: 8214883 Medline TA: Magn Reson Imaging Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 587-600 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Affiliation:
|
Vanderbilt University Institute of Imaging Science AA1105 MCN, Vanderbilt University Nashville, TN 37232-2310, USA. john.gore@vanderbilt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Brain Neoplasms / diagnosis, pathology Breast Neoplasms / diagnosis, pathology Contrast Media / pharmacology Diagnostic Imaging / methods Female Humans Magnetic Resonance Imaging / methods*, trends Male Medical Oncology / methods Membrane Proteins / metabolism Molecular Imaging / methods*, trends Neoplasms / diagnosis*, pathology* Tumor Markers, Biological / metabolism* |
| Grant Support | |
ID/Acronym/Agency:
|
CA109106/CA/NCI NIH HHS; CA127349/CA/NCI NIH HHS; CA127599/CA/NCI NIH HHS; CA128323/CA/NCI NIH HHS; CA129961/CA/NCI NIH HHS; CA138599/CA/NCI NIH HHS; CA140628/CA/NCI NIH HHS; CA142565/CA/NCI NIH HHS; CA145138/CA/NCI NIH HHS; EB000214/EB/NIBIB NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contrast Media; 0/Membrane Proteins; 0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quantitative T(1)(?) imaging using phase cycling for B(0) and B(1) field inhomogeneity compensation.
Next Document: Generalized equation for describing the magnetization in spoiled gradient-echo imaging.